Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 76 citing articles:

Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
Shuqiang Yuan, Run‐Cong Nie, Ying Jin, et al.
Nature Medicine (2024) Vol. 30, Iss. 2, pp. 552-559
Closed Access | Times Cited: 47
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial
Y.L. Verschoor, Joris van de Haar, José G. van den Berg, et al.
Nature Medicine (2024) Vol. 30, Iss. 2, pp. 519-530
Open Access | Times Cited: 46
Application of artificial intelligence for improving early detection and prediction of therapeutic outcomes for gastric cancer in the era of precision oncology
Zhe Wang, Yang Liu, Xing Niu
Seminars in Cancer Biology (2023) Vol. 93, pp. 83-96
Closed Access | Times Cited: 45
Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial
Jian‐Xian Lin, Yi-Hui Tang, Hua‐Long Zheng, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 21
Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics
Gang Che, Jie Yin, Wankun Wang, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101080-101080
Closed Access | Times Cited: 16
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
Zhaoqing Tang, Yan Wang, Dan Liu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 63
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
Jia Wei, Xiaofeng Lu, Qin Liu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 26
Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects
Wanting Hou, Yaqin Zhao, Hong Zhu
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15321-15321
Open Access | Times Cited: 23
Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study
Ning Li, Zhi Li, Qiang Fu, et al.
International Journal of Surgery (2024) Vol. 110, Iss. 4, pp. 2071-2084
Open Access | Times Cited: 11
Efficacy and safety of camrelizumab combined with oxaliplatin and S‐1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single‐arm study
Wen‐Jin Zhong, Jianan Lin, Chu‐Ying Wu, et al.
Cancer Medicine (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 9
Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial
Zhichao Jiang, Yibin Xie, Wen Zhang, et al.
Gastric Cancer (2024) Vol. 27, Iss. 3, pp. 571-579
Open Access | Times Cited: 8
Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer
Ning Zhang, Chunyu Li, Zehua Zhao, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 1
Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies
Jiawei Song, Jun Zhu, Yu Jiang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025) Vol. 1880, Iss. 2, pp. 189277-189277
Closed Access | Times Cited: 1
Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
Honghai Guo, Pingan Ding, Chenyu Sun, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 32
Therapeutic strategies for gastric cancer targeting immune cells: Future directions
Yan Zhao, Yuansong Bai, Meili Shen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 28
Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022
Yizhen Chen, Yifan Chen, Song Tan, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 18
The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: a multicenter Real-world clinical study
Yuqin Sun, Qing Zhong, Chen-Bin Lv, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 7
Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trial
Yuzhou Zhao, Danyang Li, Jing Zhuang, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 5
Open Access | Times Cited: 6
PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
Yingzi Zhang, Yan Yang, Yiran Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 23
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
Quanying Tang, Shikang Zhao, Ning Zhou, et al.
International Journal of Oncology (2023) Vol. 62, Iss. 4
Open Access | Times Cited: 16
Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials
Run‐Cong Nie, FoPing Chen, Mariano Provencio, et al.
European Journal of Cancer (2023) Vol. 186, pp. 211-221
Open Access | Times Cited: 15
Evaluation of neoadjuvant immunotherapy in resectable gastric/gastroesophageal junction tumors: a meta-analysis and systematic review
Jincheng Wang, Ti Tong, Guangxin Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma
Cameron N. Fick, Elizabeth G. Dunne, Smita Sihag, et al.
The Annals of Thoracic Surgery (2024) Vol. 118, Iss. 1, pp. 130-140
Closed Access | Times Cited: 5
Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort
Qi Jiang, Weizhen Liu, Xiangyu Zeng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis
Hao Xu, Tengyun Li, Guoyi Shao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top